Dendreon (DNDN +28.6%) takes off after providing a business update. While the drug developer...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Dendreon (DNDN +28.6%) takes off after providing a business update. While the drug developer says its Q4 product revenue only amounted to ~$82M (below an $88.9M consensus), it says it expects modest Q/Q growth (consensus is for revenue to decline to $77.9M) thanks to strong uptake for its Provenge prostate cancer drug, and says it has "sufficient cash-on-hand to meet our needs."